Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 11, 2007. The report details a corporate action regarding the application for block listings of ordinary shares on the London Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a share issuance application rather than a financial performance report.
Material Changes
The material change reported is the application to the UK Listing Authority and the London Stock Exchange for block listings totaling 35,000,000 Ordinary shares of 25p each. These shares are to be admitted to the Official List upon issuance and will rank equally with existing issued shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, or contingencies. The shares are designated for issuance under two specific plans:
- 30,000,000 shares under the GlaxoSmithKline Share Option Plan - ADS.
- 5,000,000 shares under the GlaxoSmithKline Share Option Plan - Ordinary shares.
Investor Verification Points
- Confirm the final admission of the 35,000,000 shares to the Official List.
- Verify the allocation of shares between the ADS and Ordinary share option plans.
- Review subsequent filings for the actual issuance date and impact on share count.